FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Last) 142 W. 5 (Street) NEW YO	ORM ORM 3. Dat 02/20	2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [ ORMP]  3. Date of Earliest Transaction (Month/Day/Year) 02/26/2019  4. If Amendment, Date of Original Filed (Month/Day/Year)								5. Relationship of Reporting Person(s) to Issuer Check all applicable)  X Director X 10% Owner X Officer (give title Other (specify below)  President and CEO  5. Individual or Joint/Group Filing (Check Applicable line)  X Form filed by One Reporting Person Form filed by More than One Reporting Person									
(City)	(3)		Zip)	D				<b>A</b>		•		f D.	<u> </u>		0				
1. Title of Security (Instr. 3)  2. Transacti Date (Month/Day				ction	Execution Date,			3. Transactic Code (Ins 8)	4. Securi		ities Acquired (A		or	5. Amou Securitie Benefici Owned Followir Reporter Transact (Instr. 3	nt of 6. Over 10		: Direct r ect (I)	7. Nature of Indirect Beneficial Ownership Instr. 4)	
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned  (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	se (Month/Day/Year)	if any	med on Date, Day/Year)	4. Transact Code (In 8)			ve es d	6. Date Exercisable an Expiration Date (Month/Day/Year)		9	d 7. Title and Amount of Securities Underlying Derivative Sec (Instr. 3 and 4		o D S	i. Price of Derivative Security Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly I	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership
					Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amoun or Numbe of Shares						
Stock Option (right to buy)	\$3.16	02/26/2019			A		196,500		(1)	0:	2/26/2029	Common Stock	196,50	0	\$0	196,50	0	D	

## Explanation of Responses:

1. The Stock Option will vest in 4 equal installments of 49,125 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022.

<u>/s/ Nadav Kidron</u> <u>02/28/2019</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $<sup>^{\</sup>star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).